The workforce reduction is expected to save the drugmaker $10 million in 2018. After the job cuts, the company will have approximately 70 employees.
“While it is difficult to undertake a restructuring, we believe through efficient use of our capital, we will have the potential to build significant value in our Factor D inhibitor portfolio,” said Achillion CEO Milind Deshpande, PhD.
In the fiscal year ended Dec. 31, 2017, the company reported an $85.2 million net loss, compared to $61.7 million in fiscal year 2016. In addition, the company reported a fourth quarter net loss of $23.2 million, compared to a net loss of $4.4 million the same period a year prior.
The drugmaker’s research and development expenses also increased in fiscal year 2017, rising to $65.1 million in comparison to the year prior, which had $59.2 million in research and development expenses.
Achillion attributes the increase in expenses to clinical trial costs for its lead drug, ACH-4471.
More articles on supply chain:
Amazon quietly launches exclusive OTC product line: 7 things to know
Roche’s diabetes app recalled over software bug: 4 things to know
Pharma deals in an era of heightened competition: 6 recent drugmaker transactions, partnerships
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.